Sino Biopharmaceutical Ltd
SMZ1
Company Profile
Business description
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
Contact
1 Harbour Road
Unit 09, 41st Floor, Office Tower, Room 4109
Convention Plaza
Wanchai
Hong Kong
HKGT: +852 28029886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21,435
Stocks News & Analysis
stocks
The strange effect of the 30% minimum capital gains tax
How the proposed CGT floor creates unexpected outcomes across different incomes.
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.70 | 38.80 | -0.43% |
| CAC 40 | 8,531.31 | 51.44 | 0.61% |
| DAX 40 | 25,799.37 | 18.52 | -0.07% |
| Dow JONES (US) | 53,055.91 | 155.84 | 0.29% |
| FTSE 100 | 10,688.16 | 36.39 | 0.34% |
| HKSE | 23,458.12 | 158.20 | -0.67% |
| NASDAQ | 26,121.16 | 288.49 | 1.12% |
| Nikkei 225 | 68,256.96 | 1,480.73 | -2.12% |
| NZX 50 Index | 13,762.79 | 0.31 | -0.00% |
| S&P 500 | 7,537.43 | 54.19 | 0.72% |
| S&P/ASX 200 | 8,803.90 | 35.50 | -0.40% |
| SSE Composite Index | 3,990.24 | 51.00 | -1.26% |